CTRI/2013/11/004152已完成未知
A multicentric, open label, randomized, balanced, two treatment, three period, three sequence, crossover, multiple dose, steady state bioequivalence study of Asenapine Sublingual Tablets, 10 mg manufactured by AMNEAL PHARMACEUTICALS, USA with Reference Product SAPHRIS® (asenapine) sublingual tablets, 10 mg manufactured by Catalent UK Swindon Zydis Ltd., Blagrove, Swindon, Wiltshire, SN5 8RU, UK; distributed by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, 08889, USA in adult human male & female patients under fasting condition.
Amneal Pharmaceuticals LLC USA0 个研究点目标入组 48 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Adult patients of either sex with age between 18 to 65 years (both inclusive) and have been taking a stable dose of asenapine maleate sublingual tablet, EQ 10 mg base twice daily therapy for at least three months.
- •2.Willing and able to comply with study visit schedule and other protocol requirements as indicated by signed written informed consent witnessed by a legally acceptable representative.
- •3.Females of childbearing (who has not completed 1 year after menopause & have not gone through hysterectomy or bilateral tubal ligation) potential must have a negative pregnancy test (at screening, before randomization and before check-in to housing) as well as must be non-lactating at screening and must agree to use an effective contraceptive method during study.
排除标准
- •The Patients with any of the following criteria should be excluded:
- •1. History of allergic or adverse reactions to asenapine maleate or olanzapine as judged by investigator
- •2. If consuming tobacco orally (spit tobacco, gutka, pan masala, pan, etc.)
- •3. A history of severe hepatic impairment, drug induced leukopenia/ neutropenia, congenital prolongation of the QT interval, cardiac arrhythmias, myocardial infarction or unstable heart disease
- •4. Concurrent primary psychiatric or neurological diagnosis, including organic mental disorder, severe tardive dyskinesia, or idiopathic Parkinsonâ??s disease
- •5. Abnormal laboratory results as below:
- •Reactive to antiHIV, HBSAg & anti HCV
- •WBC count 4000/μL or mm3
- •ANC count 2000/μL or mm3
- •SGPT/ SGOT 2.5 times UNL
- •Serum creatinine 1.5 times UNL
- •Hyperprolactinemia
- •QTc interval 500 ms (at screening or randomization)
- •6. A history of granulocytopenia or myeloproliferative disorders (drug-induced or idiopathic)
- •7. A medical or surgical condition that might interfere with the absorption, metabolism, or excretion of asenapine maleate
- •8. History of multiple syncopal episodes
- •9. History of epilepsy or risk for seizures
- •10. Any condition/ Abnormal baseline findings that in the investigatorsâ?? judgment might increase the risk to the patient (e.g. Significant orthostatic hypotension defined as a drop in systolic blood pressure of 30 mm Hg or more and/or a drop in diastolic blood pressure of 20 mm Hg or more on standing) or decrease the chance of obtaining satisfactory data needed to obtain the objective of the study.
- •11. A history of alcohol or drug dependence by DSM-IV criteria during the 6-month period immediately prior to study entry
- •12. Positive tests for drug or alcohol abuse at screening or baseline
- •13. Use of any of the following medication in the 14 days preceding enrolment:
- •Strong CYP3A4 inhibitors
- •Strong CYP3A4 inducers
- •CYP1A2 inhibitors
- •Antihypertensive medication or any medication that might predispose to orthostatic hypotension
- •Drugs known to suppress bone marrow function
- •Medications known to prolong the QTc interval.
- •14. Participation in any other clinical study or receipt of treatment with any investigational drug or device within 1 month prior Screening.
- •15. Blood donation/ loss exceeding 550 mL within last 90 days.
- •16. Any expected changes in concomitant medications during the period of study
- •17. Compliance with outpatient medication schedule not expected
研究者
相似试验
进行中（未招募）
1 期
Comparative pharmacokinetics study (study to know the amount of study drug (cyclophosphamide) in your blood at specified time points – to understand what body does to this study drug) of two products of cyclophosphamide powder for oral solution and Cyclophosphamide Tablets 50 mg in adult patients with breast cancerAdult female patients with breast cancer.MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-004897-77-Outside-EU/EEAIntas Pharmaceuticals Ltd.
已完成
不适用
A study of cyclophosphamide powder for oral solution in adult patients with breast cancer.CTRI/2021/11/037948Intas Pharmaceuticals LtdIndia
尚未招募
不适用
A Study of Clozapine Extended Release Capsule 200 mg Once Daily in Adult Schizophrenic Patients.CTRI/2019/11/022073Intas Pharmaceuticals Limited
尚未招募
不适用
Comparative bioavailability study of Etoposide Capsules 100 mg in adult patients with platinum resistant or refractory ovarian cancer.CTRI/2022/05/042819Intas Pharmaceuticals Ltd India
进行中（未招募）
不适用
An Open Label, Balanced, Randomized, Multi-centric, Two-Treatment, Two-Sequence, Two-Period, Single Dose, Crossover bioequivalence Study in adult human patients with Rheumatoid Arthritis (RA) who are on a regimen of oral Azathioprine under fasting condition.CTRI/2018/08/015374InvaTech Pharma Solutions LLC